Oncolytics Biotech Inc. is followed by the analysts listed below. Please note that any opinions, estimates or forecasts regarding Oncolytics Biotech Inc.’s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Oncolytics Biotech Inc. or its management. Oncolytics Biotech Inc. does not by its reference below or by any other actions imply its endorsement of or concurrence with such information, conclusions or recommendations.
| Firm | Analyst |
| Echelon Wealth Partners Inc. | Douglas Loe, PhD, MBA |
| Canaccord Genuity | Neil Maruoka, MA, MBA |
| RBC Capital Markets | Douglas Miehm |
| Paradigm Capital | Rahul Sarugaser |
Oncolytics Biotech® Announces Poster Presentation at the 2018 Gastrointestinal Cancers Symposium Sponsored by ASCO in Patients with Relapsed Metastatic Adenocarcinoma of the Pancreas Read More
Oncolytics Biotech® Receives Favorable Final Advice Letter from the European Medicines Agency for REOLYSIN® in Metastatic Breast Cancer Read More
Exploring REOLYSIN®’s Objective Response Rate in Females with Colorectal Cancer Read More
Sorry, there was a problem. Twitter returned the following error message:
Could not authenticate you.